Published in Expert Opin Ther Targets on January 12, 2012
Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer. Proc Natl Acad Sci U S A (2013) 1.32
Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev (2014) 1.16
Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res (2013) 1.12
MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways. Br J Cancer (2013) 1.07
MiRNA-181b suppresses IGF-1R and functions as a tumor suppressor gene in gliomas. RNA (2013) 1.06
A novel antisense long noncoding RNA within the IGF1R gene locus is imprinted in hematopoietic malignancies. Nucleic Acids Res (2014) 0.98
A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol (2013) 0.95
The links between insulin resistance, diabetes, and cancer. Curr Diab Rep (2013) 0.92
Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC Cancer (2013) 0.92
Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget (2016) 0.91
MicroRNA and signal transduction pathways in tumor radiation response. Cell Signal (2013) 0.87
Development of IGF signaling antibody arrays for the identification of hepatocellular carcinoma biomarkers. PLoS One (2012) 0.87
Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation. Front Endocrinol (Lausanne) (2015) 0.85
Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo. Anticancer Agents Med Chem (2013) 0.83
Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma. PLoS One (2014) 0.83
A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening. Genome Med (2014) 0.82
Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma. Int J Mol Sci (2016) 0.82
Baculovirus-mediated miRNA regulation to suppress hepatocellular carcinoma tumorigenicity and metastasis. Mol Ther (2014) 0.82
Regulation of IGF -1 signaling by microRNAs. Front Genet (2015) 0.81
Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors. BMC Cancer (2015) 0.79
p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines. Cancer Chemother Pharmacol (2015) 0.78
GSK1904529A, an insulin-like growth factor-1 receptor inhibitor, inhibits glioma tumor growth, induces apoptosis and inhibits migration. Mol Med Rep (2015) 0.77
The Potent Humanin Analogue (HNG) Protects Germ Cells and Leucocytes While Enhancing Chemotherapy-Induced Suppression of Cancer Metastases in Male Mice. Endocrinology (2015) 0.76
IGF-1 protects tubular epithelial cells during injury via activation of ERK/MAPK signaling pathway. Sci Rep (2016) 0.76
Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma. Oncotarget (2016) 0.75
Regulation of insulin-like growth factor 1 receptor signaling by microRNA-4458 in the development of lumbar disc degeneration. Am J Transl Res (2016) 0.75
Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma in vitro and in vivo. Oncoimmunology (2017) 0.75
Insulin-like growth factor 1 antagonizes lumbar disc degeneration through enhanced autophagy. Am J Transl Res (2016) 0.75
Snail modulated miR - 493 forms a negative feedback loop with IGF1R pathway and blocks tumorigenesis. Mol Cell Biol (2016) 0.75
Insulin-like growth factor 1 regulates growth of endometrial carcinoma through PI3k signaling pathway in insulin-resistant type 2 diabetes. Am J Transl Res (2016) 0.75
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell (2002) 5.58
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell (2009) 3.18
The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol (2010) 2.59
Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med (2011) 2.25
Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol (2009) 2.14
Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. Mol Cell Biol (2006) 1.93
E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res (2007) 1.70
Desmoplastic small round cell tumor of the lung. Arch Pathol Lab Med (2002) 1.65
ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages. Semin Cancer Biol (2005) 1.55
Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney. Hum Mol Genet (2004) 1.46
Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. J Mol Diagn (2007) 1.31
LEDGF (p75) promotes DNA-end resection and homologous recombination. Nat Struct Mol Biol (2012) 1.27
Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res (2002) 1.25
A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer (2004) 1.24
Proteasome-mediated cleavage of the Y-box-binding protein 1 is linked to DNA-damage stress response. EMBO J (2005) 1.23
Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle (2009) 1.21
Y-box binding protein 1: providing a new angle on translational regulation. Cell Cycle (2006) 1.20
Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors. Oncogene (2002) 1.14
Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas. Cancer Res (2004) 1.12
The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase. Mol Cell Biol (2006) 1.10
IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. Sci Signal (2012) 1.09
Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res (2010) 1.08
Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol (2003) 1.07
Identification and quantification of newly synthesized proteins translationally regulated by YB-1 using a novel Click-SILAC approach. J Proteomics (2012) 1.06
ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway. Cancer Res (2010) 1.02
Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry. Hum Pathol (2003) 1.00
Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity. Mol Cell Biol (2004) 0.99
ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation. Oncogene (2002) 0.99
Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy. Med Pediatr Oncol (2003) 0.95
Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Am J Surg Pathol (2007) 0.93
A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation. J Biol Chem (2003) 0.92
Understanding micrometastatic disease and Anoikis resistance in ewing family of tumors and osteosarcoma. Oncologist (2010) 0.92
Small round cell sarcomas. Semin Oncol (2009) 0.92
Classification of malignant pediatric renal tumors by gene expression. Pediatr Blood Cancer (2006) 0.91
Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src. Cancer Res (2007) 0.91
Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer. Mol Cancer Res (2011) 0.90
TRAIL promotes membrane blebbing, detachment and migration of cells displaying a dysfunctional intrinsic pathway of apoptosis. Apoptosis (2013) 0.89
The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-beta signaling by inactivating the TGF-beta type II receptor. Proc Natl Acad Sci U S A (2005) 0.87
On translational regulation and EMT. Semin Cancer Biol (2012) 0.86
Mediators of receptor tyrosine kinase activation in infantile fibrosarcoma: a Children's Oncology Group study. J Pathol (2012) 0.85
Ubiquitous expression of the monomeric red fluorescent protein mCherry in transgenic mice. Genesis (2010) 0.84
A possible role for long non-coding RNA in modulating signaling pathways. Med Hypotheses (2011) 0.82
Cryptic t(X;18), ins(6;18), and SYT-SSX2 gene fusion in a case of intraneural monophasic synovial sarcoma. Cancer Genet Cytogenet (2002) 0.82
Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Mol Cancer Ther (2010) 0.82
Sarcomas with spindle cell morphology. Semin Oncol (2009) 0.82
ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype. Br J Haematol (2002) 0.75
Characterization of NKIP: a novel, Na+/K+-ATPase interacting protein mediates neural differentiation and apoptosis. Exp Cell Res (2007) 0.75